Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says

 
• By Jessica Merrill

Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.

heart versus money
positive CV data could make Wegovy a better value to payers • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas